2020
Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation
Tegel BR, Huber S, Savic LJ, Lin M, Gebauer B, Pollak J, Chapiro J. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation. Acta Radiologica 2020, 61: 1708-1716. PMID: 32216452, PMCID: PMC7529766, DOI: 10.1177/0284185120909964.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellContrast MediaDisease ProgressionFemaleHumansImaging, Three-DimensionalKidney NeoplasmsMaleMiddle AgedNeoplasm StagingRadiography, InterventionalRetrospective StudiesSensitivity and SpecificityTumor BurdenUltrasonography, InterventionalConceptsProgression-free survivalTotal tumor volumeRenal cell carcinomaCell carcinomaOdds ratioTumor volumeImaging biomarkersImage-guided thermal ablationPrognosis of patientsRENAL nephrometry scoreCox regression modelLargest tumor diameterLog-rank testKaplan-Meier plotsCross-sectional imagingSensitive imaging biomarkerMetastatic diseaseSecondary outcomesPrimary outcomeDistant metastasisNephrometry scoreTumor diameterOutcome parametersLesion vascularityTNM stage
2018
Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study
Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C. Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal Of Vascular And Interventional Radiology 2018, 29: 1646-1653.e5. PMID: 30337148, DOI: 10.1016/j.jvir.2018.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorChemoembolization, TherapeuticColorectal NeoplasmsConnecticutDrug CarriersFeasibility StudiesFemaleHumansIrinotecanLiver NeoplasmsMaleMicrospheresMiddle AgedPalliative CareProspective StudiesTime FactorsTomography, X-Ray ComputedTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ConceptsVascular endothelial growth factor receptor 1Transarterial chemoembolizationAdverse eventsMetastatic diseaseObjective responseColorectal cancer liver metastasesLiver-dominant metastatic diseaseMetastatic colorectal cancer refractorySingle-center phase IColorectal cancer refractoryLines of chemotherapyMedian overall survivalPrimary end pointCancer liver metastasesResponse Evaluation CriteriaOnly grade 3Drug-eluting embolicsImaging-based criteriaGrowth factor receptor 1Factor receptor 1World Health OrganizationCancer refractoryAbdominal painSystemic chemotherapyLiver metastases
2016
Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT
Schernthaner RE, Haroun RR, Duran R, Lee H, Sahu S, Sohn JH, Chapiro J, Zhao Y, Gorodetski B, Fleckenstein F, Smolka S, Radaelli A, van der Bom IM, Lin M, Geschwind JF. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT. CardioVascular And Interventional Radiology 2016, 39: 1429-1437. PMID: 27380872, PMCID: PMC5009166, DOI: 10.1007/s00270-016-1406-2.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyDigital subtraction angiographyLiver metastasesDP-CBCTCone-beam CTDual-phase cone-beam CTContrast-enhanced magnetic resonance imagingSarcoma liver metastasesTumor-feeding arteriesMagnetic resonance imagingContrast agent injectionMetastatic diseaseMethodsThis IRBRetrospective studyCRCLMClinical impactArterial phaseCE-MRIDepiction rateResonance imagingAgent injectionSubtraction angiographyMetastasisTherapyHigh rate